Assessment of aloe vera for qualitative fit testing of particulate respirators: a logistic regression approach

Anahita Fakherpour 1, Mehdi JAHANGIRI 2*, Saeed Yousefinejad 3, Mozhgan Seif 4, Sean Banaee 5

1 Department of Occupational Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
2* Department of Occupational Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Corresponding author: Tel:+98-9191145280; E-mail: jahangiri_m@sums.ac.ir. P.O. Box 7153675541
3 Department of Occupational Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
4 Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
5 Community and Environmental Health, College of Health Sciences, Old Dominion University, Norfolk, Virginia, USA.

Received: February 1, 2019
Accepted: May 14, 2019
Advance publication: June 1, 2019
Abstract: Fit testing procedure is required for filtering facepiece respirators (FFRs) to ascertain an acceptable fit between the skin and facepiece sealing surface. The present study seeks to compare the efficacy of Aloe vera (A. vera) and commercial Bitrex™ as challenge agents of qualitative fit testing of particulate respirators. An herbal solution consisting of A. vera at seven different concentrations was developed. Threshold Screening Tests (TSTs) of A. vera solutions were compared to Bitrex™. To do so, solutions were administered randomly on a total of 62 participants. A placebo was also tested to ensure the taste response being valid. Statistical analysis was performed using R 3.2.5.0 software. There were no statistically significant differences between the A. vera (41.7, 58.3, 75, and 91.7 mg/ml) and Bitrex™ threshold tests. Therefore, the minimum concentration of A. vera to develop the threshold solution was considered to be 41.7 mg/ml. When commercial products are expensive and unavailable, a cost-effective technique would be to replace A. vera solution with a commercial product as a challenge agent of qualitative fit testing of respirators.

Key words: Qualitative Fit test, Challenge agents, Commercial and Herbal solutions
Introduction

Efficient respiratory protection is dependent mainly on the filters or cartridges efficiency as well as appropriateness for users’ face and work environment\textsuperscript{1,3}). According to the Occupational Safety and Health Administration (OSHA), it is mandatory to make sure there is an appropriate fit between a respirator’s facepiece and face seal. To meet the legal requirements, it is necessary to do fit testing for all subjects included in the Respiratory Protection Program (RPP) before the respirator selection\textsuperscript{4}). The ability of the respirator to interface with the users’ face to protect the respiratory system against hazardous contaminants, named “Respirator fit”\textsuperscript{5}).

There are mainly two assessment methods of respirator fit testing per OSHA standard (29 CFR 1910.134), to provide the expected level of protection for the wearers\textsuperscript{6)}: Qualitative fit test (QLFT) and Quantitative fit test (QNFT). QNFT uses an instrument to measure the fit factor by dividing the ambient particle concentration by the concentration of particles inside the facepiece of the respirator while the user performs a series of simulated work exercises\textsuperscript{4}). QNFT has some advantages such as application to various classes of Respiratory Protective Equipment (RPE)\textsuperscript{7)}, documentation of numerical results, and no chance of deception\textsuperscript{8}). However, due to high cost, time-consuming, skilled operator, unavailability\textsuperscript{5)}, annual recalibration, and reliance on a sampling adaptor or probed respirator, QLFT is widely being used as the preferred method\textsuperscript{4,9,10)}.

QLFT is a dichotomous test (pass/fail) that depends on the wearer’s olfactory or taste response to a challenge agent during the same series of exercises as the QNFT. Currently, there are three common challenge agents including isoamyl acetate; saccharin; and Bitrex\textsuperscript{TM}. Isoamyl acetate (IAA), a sweet (banana) smelling vapor is used in qualitative fit testing of respirators equipped with organic vapor cartridges; whereas, saccharin (sweet taste) and Bitrex\textsuperscript{TM} (bitter taste) are the challenge agents for fit testing of respirators equipped with particulate filters\textsuperscript{4}). Moreover, Bitrex\textsuperscript{TM}, the trade name of the bitterest substance, denatonium benzoate (Smith Ltd., Montvale, NJ McFarland), generally used as an aversive agent in toxic household liquids to decrease the risk of accidental poisoning\textsuperscript{4}).

The most substantial concern about the QLFT is its subjective nature. It is impossible to do fit testing for all subjects in
events like pandemics \textsuperscript{11}). It should be mentioned that the QLFT is simpler to use \textsuperscript{11,12}, and cheaper to set up and maintain \textsuperscript{12} than QNFT. But some of the challenge agents like Bitrex\textsuperscript{TM} lead to allergic (asthmatic) reactions \textsuperscript{13,14}, dermal and respiratory symptoms, anaphylactic reactions (angioedema and bronchospasm), and anxiety response or even an inability to detect the taste/smell of the agents \textsuperscript{13}).

Remarkably, some qualifications should be considered for selecting a qualitative challenge agent as follows: cost-benefit, availability, safety, suitability for human exposure, and ability to use with any type of approved particular filter \textsuperscript{12}). Commercial challenge agents would not be cost-beneficial or available, furthermore, they might be led to symptoms and complications in some subjects as mentioned above. Consequently, the efficacy of A. vera was compared to Bitrex\textsuperscript{TM}.

A. vera is a shining or bitter substance, bitter because of liquids such as Aloin, Aloe emodin, and related compounds in the leaves\textsuperscript{15-17}). It is approved as Generally Recognized as Safe (GRAS) in the US by the Food and Drug Agency (FDA) \textsuperscript{16,18} and World Health Organization (WHO) \textsuperscript{18,19}). It exerts beneficial effects on human health, including: anti-inflammatory \textsuperscript{17,18,20-25}, antimicrobial \textsuperscript{18,22-24,26}, antifungal \textsuperscript{17,18}, antioxidant and antitumor \textsuperscript{23,27}, anticancer \textsuperscript{17,23,26,28}, and immunomodulatory properties \textsuperscript{17,23,24}). It seems that A. vera could be the right substitute for Bitrex\textsuperscript{TM} as a challenge agent. Also, as stated in ISO 16975-3 \textsuperscript{9}), equivalent substances could be used as challenge agents if they behave similar and show identical results. Accordingly, the aim of this study was to compare the efficacy of A. vera against Bitrex\textsuperscript{TM} as a qualitative fit test agent.

**Subjects and Methods**
**Study design**

We conducted a single-blind, placebo-controlled, and interventional study at Shiraz University of Medical Sciences, Iran.

**Participants**

Sixty-two students (37 females and 25 males), mean age 23.45 ± 4.66 years, using a proportional stratified sampling method based on their educational level, were recruited for the study. The participants were tested in the Industrial Safety laboratory of the School of Health.

First of all, the procedures of this study were approved by the Research Ethics Committee of Shiraz University of Medical Sciences (approval code IR.SUMS.REC.1396.191). Second, all participants were provided explanation about study procedures. Then, each was given written informed consent documentation. The criteria included an absence of the following: (1) allergy to any substance; (2) cold symptoms; (3) nasal congestion; (4) cardiovascular or respiratory diseases (asthma, shortness of breath, dyspnea); 29) rhinoplasty surgery, or (6) other factors interfering with the sense of taste. If any participant developed a cold, the test session was postponed until his/her recovery.

**Study procedure**

All participants refrained from chewing gum, eating, and drinking (except for plain water) for 15 minutes prior to the test to ensure they could taste the threshold check solution (a diluted version of the fit test solution). Meanwhile, the placebo solution (distilled water) was tested among the solutions randomly to be sure the participants could distinguish it. To obtain reliable results, the test assessor reminded participants to drink only plain water. A 5-min break also allowed participants to clear their palates between test solutions. These ed complementary tests were illustrated further:

1) To make certain the threshold check solutions hadn’t been contaminated, the microbial communications of the solutions were assessed. To do so, we utilized the Blood Agar for bacteria 30 and Sabouraud Dextrose Agar 31 (Merck Co., Germany) for fungus.
2) The taste of the solutions was evaluated continuously.
3) The optical molecular spectra of the solutions was observed regularly using Agilent Cary 60 spectrophotometer (Agilent Technologies, Santa Clara, USA) at 25 °C in the wavelength...
range of 200-800 nm to follow up the stability of the solutions regarding color, clarity and not construction of unstable colloids during the ten months which were presented in the supplementary materials “Fig-S1-S8”.

4) The pH of the solutions was measured using a Metrohm pH meter model 827 (Metrohm, Herisau, Switzerland), according to manufacturer’s instructions (Table 1).

Threshold Check Solution Preparation

Nine different threshold check solutions, including A. vera (7 concentrations), a Bitrex™, and a placebo, were made. We found that limited amounts of A. vera could not significantly affect the taste of the solutions; therefore, they were considered for the range of applied concentrations of the A. vera threshold check solutions. The threshold check solutions were poured into identical bottles and labeled with unique codes by the administrator. Those solutions were randomly allocated to the participants based on the Latin Square Design (LSD) 12). Accordingly, all possible permutation of solutions was 9 factorial (9!). Also, all participants were blinded to the ingredient and concentration of each solution.

Bitrex™ Threshold Check Solution

Moldex® Bitrex® Fit Test Kit Part number 0102 (Moldex Co., Culver, CA) contained 0.0135% denatonium benzoate, 94.9865 % water, and 5% sodium chloride 32).

Aloe vera Threshold Check Solution

We chose the A. vera as equivalent to Bitrex™. A. vera solutions were prepared by adding 1.28, 2.26, 3.15, 5, 7, 9, and 11 gr of A. vera powder to 120 ml of distilled water. The above mixtures were boiled at 100 °C for 10 min. After the solutions had been cooled, they were passed through a stainless sieve (US Standard Sieve Mesh No. 200 (0.075 mm), Pars Sieve, Iran; ASTM E:11). Indeed, the final concentrations of the threshold check solutions were 10.7, 18.8, 26.2, 41.7, 58.3, 75, and 91.7 mg/ml, respectively.

Threshold Screening Tests

Threshold Screening Tests (TSTs) were performed per OSHA respiratory protection standard, regulation 29
CFR 1910.134 4). The TSTs were aimed to ensure the participants’ taste response being valid. Some accessories are required to do the TSTs, for instance, hood, nebulizer, and paper towel. The poly-coated test hood is approximately 12 inches (30.5 cm) in diameter by 14 inches (35.6 cm) and was placed over a participant’s head and positioned forward about 6 inches (15.25 cm) between the participant’s face and hood window. The 0.75 inch (1.9 cm) hole in front of the participant’s nose and mouth area accommodated the nebulizer nozzle and dispersed the aerosol with a 2.5 µm mass median aerodynamic diameter (MMAD) around the participant’s mouth 9) (Fig 1.). Moreover, the nebulizers were periodically checked for aerosol generation while squeezing the bulbs. To do so, they were held against a dark background to ensure the visible aerosol appears. The nebulizers were disassembled based on the manufacturer’s manual and rinsed at regular intervals to prevent clogging. The hood was wiped frequently with a paper towel to clean any deposited solution.

Fig. 1. Moldex fit test hood used in the current study

Prior to starting the intervention, firstly, the participants were trained to position the hood over the head without donning a respirator, breathing only through their mouths slightly open with tongue extended and to report as soon as they could detect the taste (not smell) of the challenge agent, however, we didn’t notify the participants about the taste of the solutions (sweet, bitter, etc.). Secondly, the challenge agent was injected in the hood via inserting ten squeezes of the nebulizer bulb into the hole in front of the hood. This requires the bulb to fully collapse and expand during each squeeze cycle. Thirdly, the participants were asked if they could detect the taste of the solution. We applied up to a total of 30 sprays if required. Also, the taste threshold was recorded as ten, twenty, or thirty regardless of the numbers of actual performed squeezes (10, 20 or 30 sprays). In other words, if the participants could taste between 1-10, 11-20, or 21-30 sprays, their threshold levels were classified into one of the three classes of High (1), Medium (2), or Low (3), respectively. If the participants couldn’t detect the taste of the solution after 30 sprays, they were not sensitive to it and their threshold test was assigned as
a failure; otherwise, a pass. The video of Moldex threshold screening procedure was played for the participants 33). Lastly, we recorded the study data such as threshold solution code, the concentration of test solutions (mg/ml), number of sprays, time required to elicit a taste response correctly (s), threshold level (1, 2 or 3), and test result (pass/fail).

**Statistical Analysis**

The input variables were as follows: type and concentration of the solutions, age, and gender. The outcome variables included the results of TSTs (pass/fail). We took repeated measures on the participants; thus, the observations were correlated and the Mixed Effect Logistic Regression (MELR) model including random effects was proposed 34). Noticeably, the model was adjusted for age and gender. We calculated the Kappa statistic (k), Brier score as the mean square error of taste detection 34), and accuracy 35) to compare the results of the TSTs. Meanwhile, a Receiver Operating Characteristic (ROC) curve analysis was obtained to evaluate the detectability of all threshold solutions against placebo (as a reference solution). The Area Under the ROC Curve (AUC) was calculated to determine the overall performance of all threshold check solutions against the placebo 35). Additionally, A. vera threshold solutions (bitter taste) were compared to Bitrex™ (as a reference solution). A p-value of 0.05 was considered significant. All data analyses were performed using R 3.2.5.0 software.
Results

Table 1 shows the TSTs descriptive statistics results. As shown, the majority of the participants could taste Bitrex™ and A. vera (75 mg/ml) solutions (96.8 % and 91.9 %, respectively). As expected, all solutions (except for placebo) were tasted within close margin, in terms of the number of sprays and detection time (s).

Table 1. Results of the Threshold Screening Tests (TSTs)

The results of all threshold solutions tests against placebo are shown in Table 2. There were significant differences between the Bitrex™ and A. vera solutions (41.7, 58.3, 75, and 91.7 mg/ml) and placebo. The OR for taste detection of Bitrex™ and A. vera (75 mg/ml) was calculated as 14.78 and 5.39, respectively. In addition, the accuracy score for the corresponding solutions was the highest as 84% (104/124) and 81% (101/124), respectively. The A. vera (75 mg/ml) held the lowest Brier score among all solutions.

The ROC curves for Bitrex™ and A. vera threshold tests against placebo are given in Fig. 2. Accordingly, the ROC curve for A. vera threshold test was similar to that of Bitrex™ (89.5% vs. 90.3%, respectively). The numbers represent the participants could detect the bitter taste of Bitrex™ and A. vera (75 mg/ml) during TSTs. This suggests that the performance of A. vera threshold solution (75 mg/ml) was similar to that of Bitrex™.

Table 2. Comparison of threshold tests against placebo by MELR™

Fig. 2. Receiver operating characteristic (ROC) curves for threshold tests against placebo: Bitrex™ (a), A. vera; 41.7 and 58.3 mg/ml (b), 75 mg/ml. (c), 91.7 mg/ml (d).

The results of A. vera threshold tests against Bitrex™ are summarized in Table 3. As seen, no significant differences
were found between the A. vera (concentration range of 41.7 to 91.7 mg/ml) and Bitrex™ threshold tests. Among all solutions, the OR for taste detection of A. vera (75 mg/ml) in comparison to Bitrex™ was the highest (OR= 0.37). The significant agreement between the Bitrex™ and A. vera (75 mg/ml) threshold tests was calculated as the highest value (k= 0.88).

Table 3. The results of A. vera threshold tests vs. commercial Bitrex™ by MELR™

Fig. 3 reveals the overall performance of Bitrex™ and A. vera threshold tests against a placebo through comparing the correspondence AUC curves. Obviously, the AUC curves for those solutions overlapped. No significant differences were observed between the Bitrex™ and A. vera threshold tests (p-value= 0.66). Since the ROC curve for the A. vera (75mg/ml) threshold solution moved to left and upside (Bitrex™), it is apparent that its efficacy is similar to that of Bitrex™ and could be employed as a qualitative fit test agent. Interestingly, the Cost-Benefit Analysis (CBA) of the current study indicates that the cost and time required to access A. vera solution were remarkably less than Bitrex™ one (Where cost is $84/100gr versus $2/100gr, and time between purchase and delivery is 1 business day versus 14 business days).

Fig. 3. Comparison of area under the ROC curves (AUC) for threshold solutions: Bitrex™ and A. vera; 75 mg/ml (a), 41.7, 58.3, and 75 mg/ml (b).

Discussion

The aim of this study is to investigate the efficacy of A. vera compared to Bitrex™ as a qualitative challenge agent. The principal points found from this research will be discussed below in more detail.

First, the proposed MELR model demonstrated that there were no statistically significant differences between the Bitrex™ and A. vera (41.7, 58.3, 75, and 91.7 mg/ml) threshold test results. This means that participants could detect the bitter taste using either Bitrex™ or A. vera solution. The minimum concentration of A. vera to develop the threshold solution was considered be 41.7 mg/ml. Accordingly,
A. vera solution could be made on-site with similar efficacy to that of Bitrex™.

Second, the degree of agreement between the results of Bitrex™ and A. vera (75 mg/ml) threshold tests was considered very good (k= 0.88) which highlights the high efficacy of A. vera in order to use as a qualitative fit test agent. This finding is consistent with the study of Brett G. Mitchell et al. 11), which states that on-site made solutions could be replaced by commercial products for qualitative fit testing of respirators. The ability to produce A. vera solution on-site is a critical factor to making a key difference in the event of an influenza pandemic or similar respiratory diseases. If the testing solution was either not readily available or too costly, the facility could incur preventable loss of both profit and life.

Another important finding has to do with the fact that the majority of the participants tasted both the Bitrex™ and A. vera (75 mg/ml) solutions. The OR for taste detection of these mentioned solutions was 14.78 and 5.39 times the OR for the placebo, respectively, meaning that the OR for taste detection of the Bitrex™ was almost 2.70 times the OR for taste detection of A. vera (75 mg/ml) solution. This means that participants were 2.70 times more likely to detect the bitter taste of Bitrex™ than that of A. vera (75 mg/ml) solution. The AUC for those solutions overlapped, which confirms that A. vera (75 mg/ml) solution has similar efficacy to that of Bitrex™.

Noticeably, Bitrex™ was detected more often than A. vera (75 mg/ml) (96.8% vs. 91.9%). This is consistent with some published studies (Mullins, 1995; Roy T. McKay, 2000) that discussed easier detectability of Bitrex™ compared with saccharin 12, 36). The mean of the sprays’ number to detect the bitter taste of Bitrex™ and A. vera (75 mg/ml) were almost the same (5.32, 6.23, respectively). We can also merge those two thoughts as “The CBA obtained from the laboratory test confirm that A. vera (75mg/ml) could be utilized as a challenge agent of qualitative fit test, which is beneficial”

The overall cost of A. vera was 42 times (97.6%) lower than that of Bitrex™. Additionally, the required time for preparation of A. vera fit test solution was lower than that of Bitrex™. In fact, on an average, 14 business days required for the commercial solution to be delivered. Whereas, the A. vera could be available about one business day.

Finally, a number of important limitations need to be considered. First, the TSTs of the current study were based on the subjective reaction to the nge agentsechall like the other
qualitative fit test solutions. Second, any variation from the fit test protocol would invalidate the test results, including the hood size, changes in the concentration of the solutions, squeezing the nebulizer bulb, and the number of squeezes.

Conclusion

This study suggests that replacing of A. vera solution with a commercial product as a challenge agent in fit testing procedure would be a cost-effective technique; due to factors as performance, cost, and availability. It should be emphasized that the studied solutions are safe for microbial communications and some physicochemical properties of the solutions (taste, color or clearance) were monitored over the course of the study and we can safely assure that these properties are constant. To do so, it is feasible to utilize the herbal solutions (i.e., A. vera) as challenge agents for qualitative fit testing of particulate respirators.

Acknowledgements

The authors gratefully acknowledge participants for their collaboration with our project.

Conflicts of Interest

None declared.

Funding

The present article was extracted from the thesis written by Anahita Fakherpour, MSc., a student of Occupational Health and was financially supported by Shiraz University of Medical Sciences, Shiraz, Iran (Grant No. 1396-01-04-15787).

References


8) Introduction to Respirator Fit Testing Available from: www.tsi.com/uploadedFiles/_Site_Root/Products/Literature/Notes/iti_070.pdf, Shoreview, MN USA,


13


Oral Dis. 23, 913-918.


J Med Assoc Thai. 4, 69-78.


G Ital Dermatol Venereol. 144, 85-91.


### Table 1. Results of the Threshold Screening Tests (TSTs)

<table>
<thead>
<tr>
<th>Solutions</th>
<th>Concentration (mg/ml)</th>
<th>pH</th>
<th>Threshold test</th>
<th>Number of sprays</th>
<th>Detection time (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pass N (%)</td>
<td>Fail N (%)</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>Placebo</td>
<td>--</td>
<td>-</td>
<td>44 (71)</td>
<td>18 (29)</td>
<td>15.68±8.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 (3.2)</td>
<td>5.32±4.18</td>
<td>22.08±11.49</td>
</tr>
<tr>
<td>Bitrex™</td>
<td>0.135</td>
<td>6.91</td>
<td>60 (96.8)</td>
<td>2 (3.2)</td>
<td>5.32±4.18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>7.96±4.96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. vera</td>
<td>10.7</td>
<td>7.50</td>
<td>52 (83.9)</td>
<td>10 (16.1)</td>
<td>7.54±6.32</td>
</tr>
<tr>
<td></td>
<td>18.8</td>
<td>7.11</td>
<td>43 (69.4)</td>
<td>19 (30.6)</td>
<td>7.65±5.83</td>
</tr>
<tr>
<td></td>
<td>26.2</td>
<td>7.02</td>
<td>43 (69.4)</td>
<td>19 (30.6)</td>
<td>8.81±7.22</td>
</tr>
<tr>
<td></td>
<td>41.7</td>
<td>6.70</td>
<td>53 (85.5)</td>
<td>9 (14.5)</td>
<td>7.04±6.016</td>
</tr>
<tr>
<td></td>
<td>58.3</td>
<td>6.43</td>
<td>53 (85.5)</td>
<td>9 (14.5)</td>
<td>6.87±4.87</td>
</tr>
<tr>
<td></td>
<td>75.0</td>
<td>6.25</td>
<td>57 (91.9)</td>
<td>5 (8.07)</td>
<td>6.23±5.68</td>
</tr>
<tr>
<td></td>
<td>91.7</td>
<td>6.14</td>
<td>53 (85.5)</td>
<td>9 (14.5)</td>
<td>4.81±3.07</td>
</tr>
</tbody>
</table>

*18 (29%) of the participants reported the placebo as a sweet, salty, or bitter taste.

### Table 2. Comparison of threshold tests against placebo by MELR

<table>
<thead>
<tr>
<th>Solutions</th>
<th>Concentration (mg/ml)</th>
<th>Coefficient (β)</th>
<th>OR^†</th>
<th>95% CI for OR</th>
<th>Accuracy</th>
<th>Brier Score</th>
<th>AUC</th>
<th>95% CI for AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>0.135</td>
<td>2.69**</td>
<td>14.78</td>
<td>3.15</td>
<td>0.18</td>
<td>0.84</td>
<td>0.90</td>
<td>0.85</td>
</tr>
<tr>
<td>Bitrex™</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. vera</td>
<td>10.7</td>
<td>-1.85†††</td>
<td>0.16</td>
<td>0.03</td>
<td>0.78</td>
<td>0.14</td>
<td>0.85</td>
<td>0.78</td>
</tr>
<tr>
<td></td>
<td>18.8</td>
<td>-2.77***</td>
<td>0.06</td>
<td>0.01</td>
<td>0.29</td>
<td>0.39</td>
<td>0.76</td>
<td>0.68</td>
</tr>
<tr>
<td></td>
<td>26.2</td>
<td>-2.77***</td>
<td>0.06</td>
<td>0.01</td>
<td>0.29</td>
<td>0.72</td>
<td>0.31</td>
<td>0.71</td>
</tr>
<tr>
<td></td>
<td>41.7</td>
<td>-1.71</td>
<td>0.18</td>
<td>0.04</td>
<td>0.09</td>
<td>0.13</td>
<td>0.85</td>
<td>0.79</td>
</tr>
<tr>
<td></td>
<td>58.3</td>
<td>-1.71</td>
<td>0.18</td>
<td>0.04</td>
<td>0.09</td>
<td>0.85</td>
<td>0.75</td>
<td>0.94</td>
</tr>
<tr>
<td></td>
<td>75.0</td>
<td>-1.00</td>
<td>0.37</td>
<td>0.07</td>
<td>2.02</td>
<td>0.88</td>
<td>0.79</td>
<td>0.97</td>
</tr>
<tr>
<td></td>
<td>91.7</td>
<td>-1.71</td>
<td>0.18</td>
<td>0.04</td>
<td>0.09</td>
<td>0.85</td>
<td>0.75</td>
<td>0.94</td>
</tr>
</tbody>
</table>

*Adjusted for age/gender
** p-value<0.0001
*** p-value<0.05

### Table 3. The results of A. vera threshold tests vs. Bitrex™ by MELR

<table>
<thead>
<tr>
<th>Solutions</th>
<th>Concentration (mg/ml)</th>
<th>Coefficient (β)</th>
<th>OR^†</th>
<th>95% CI for OR</th>
<th>Kappa (k)</th>
<th>95% CI for Kappa</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bitrex™</td>
<td>0.135</td>
<td>2.69**</td>
<td>14.78</td>
<td>3.15</td>
<td>0.18</td>
<td>0.84</td>
</tr>
<tr>
<td>A. vera</td>
<td>10.7</td>
<td>-1.85†††</td>
<td>0.16</td>
<td>0.03</td>
<td>0.78</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td>18.8</td>
<td>-2.77***</td>
<td>0.06</td>
<td>0.01</td>
<td>0.29</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>26.2</td>
<td>-2.77***</td>
<td>0.06</td>
<td>0.01</td>
<td>0.29</td>
<td>0.72</td>
</tr>
<tr>
<td></td>
<td>41.7</td>
<td>-1.71</td>
<td>0.18</td>
<td>0.04</td>
<td>0.09</td>
<td>0.13</td>
</tr>
<tr>
<td></td>
<td>58.3</td>
<td>-1.71</td>
<td>0.18</td>
<td>0.04</td>
<td>0.09</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>75.0</td>
<td>-1.00</td>
<td>0.37</td>
<td>0.07</td>
<td>2.02</td>
<td>0.88</td>
</tr>
<tr>
<td></td>
<td>91.7</td>
<td>-1.71</td>
<td>0.18</td>
<td>0.04</td>
<td>0.09</td>
<td>0.85</td>
</tr>
</tbody>
</table>

*Adjusted for age/gender
** p-value<0.05
*** p-value<0.0001
Fig. 1. Moldex fit test hood used in the current study
Fig. 2. Receiver operating characteristic (ROC) curves for threshold tests against placebo: commercial Bitrex™ (a), A. vera; 41.7 and 58.3 mg/ml (b), 75 mg/mL (c), 91.7 mg/ml (d).
Fig. 3. Comparison of area under the ROC curves (AUC) for threshold solutions: commercial Bitrex™ and A. vera; 75 mg/ml (a), 41.7, 58.3, and 75 mg/ml (b).
S1: Commercial Bitrex\textsuperscript{TM} (0.135 mg/ml)

S2: A. vera (10.7 mg/ml)

S3: A. vera (18.8 mg/ml)

S4: 26.2 mg/ml
Fig S1-S8. The optical molecular spectra of the threshold solutions (UV-Vis)